January 2014: Spinomix announces a milestone payment from Debiopharm Group™ and the appointment of a new CEO

Lausanne, Switzerland – January 8, 2014 – Spinomix SA, a Swiss company advancing molecular diagnostic through innovative sample preparation technologies and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the successful achievement of a second development milestone on Spinomix’ two proprietary technologies, namely MagPhase™ and FibroTrap™. In conjunction with the terms of the investment agreement, Spinomix is to receive an undisclosed second tranche payment from Debiopharm.